~~<i id='39D087DD0C'><strike id='39D087DD0C'><tt id='39D087DD0C'><pre id='39D087DD0C'></pre></tt></strike></i>~~

Home» focus» hotspot

hotspot

author：knowledge 2025-09-28 02:45:03 Page View：6694

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 6 phony surgeries that take placebo to the extreme
Next article： Anesthesiologist group: stop taking Ozempic before surgery

leisure time

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

Mass General Brigham physicians react to latest merger step

SuhasGondiofBrighamandWomen'sHospitalhasresearchedandwrittenabouthospitalboardsincreasinglybeingmade

Continuity nursing helped my family in our darkest PICU moments

EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3

U.K. decision on ALS drug has neurologists, advocates up in arms

TheALSdrugtofersenismarketedasQalsodyintheU.S.BiogenLONDON—Neurologistsandpatientadvocatesareupinarm